The term nocebo effect refers to the harmful outcomes that result from people's negative beliefs, anticipations, or experiences related to the treatment rather than the pharmacological properties of the treatment. These outcomes may include a worsening of symptoms, a lack of expected improvement, or adverse events, and they may occur after the active treatment and the placebo that is supposed to imitate it. The nocebo effect is always unwanted and may distort estimates of treatment effectiveness and safety; moreover, it may cause discontinuation of therapy or withdrawal from a trial. The nocebo effect may be unintentionally evoked by the explanations given by healthcare professionals during a clinical consultation or consent procedures, or by information from other patients, the media, or the Internet. Moreover, it may be a consequence of previous bad experiences with the treatment, through learning and conditioning, and the conditioning may happen without patients' conscious awareness. In trial settings, a study design, for example lack of blinding, may introduce bias from the nocebo effect. Unlike the placebo effect, which is usually taken into consideration while interpreting treatment outcomes and controlled for in clinical trials, the nocebo effect is under-recognised by clinical researchers and clinicians. This is worrying, because the nocebo phenomenon is common and may have potentially negative consequences for the results of clinical treatment and trials. It is therefore important that doctors and medical researchers consider any potential nocebo effect while assessing the treatment effect and try to minimise it through careful choice and phrasing of treatment-related information given to patients.
Keywords: Adverse Events in Clinical Trials; Nocebo Effect; Placebo Group; Randomised Clinical Trial (RCT); Review (article).
Conflict of interest statement
No competing interests were disclosed.
Nocebo effects in the treatment of major depression: results from an individual study participant-level meta-analysis of the placebo arm of duloxetine clinical trials.J Clin Psychiatry. 2015 Jun;76(6):702-11. doi: 10.4088/JCP.13r08858. J Clin Psychiatry. 2015. PMID: 26132671
Medical Error Prevention.2020 Feb 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. StatPearls. 2020 Jan–. PMID: 29763131 Free Books & Documents. Review.
Do randomized clinical trials with inadequate blinding report enhanced placebo effects for intervention groups and nocebo effects for placebo groups?Syst Rev. 2014 Feb 21;3:14. doi: 10.1186/2046-4053-3-14. Syst Rev. 2014. PMID: 24555576 Free PMC article.
The nocebo effect in the context of statin intolerance.J Clin Lipidol. 2016 Jul-Aug;10(4):739-747. doi: 10.1016/j.jacl.2016.05.002. Epub 2016 May 13. J Clin Lipidol. 2016. PMID: 27578103 Review.
Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions.J Cachexia Sarcopenia Muscle. 2018 Dec;9(6):1023-1033. doi: 10.1002/jcsm.12344. Epub 2018 Oct 11. J Cachexia Sarcopenia Muscle. 2018. PMID: 30311434 Free PMC article.